The Evaluation of Ischemia Modified Albumin and Adropin Levels in Patients with Pulmonary Embolism

Abstract

Background: Pulmonary embolism (PE) is a serious clinical condition and difficult to be diagnosed. The aim of the present study was to evaluate serum adropin and ischemia-modified albumin (IMA) levels in the patients with PE. Materials and Methods: The study consisted of 109 participants, including 50 patients with PE and 59 healthy individuals. The patients diagnosed with PE through computed tomography pulmonary angiography (CTPA) were included into the study. Serum adropin and IMA concentrations were measured by an enzyme-linked immunosorbent assay kit. Results: The patients with PE had higher serum adropin (607.5±205.1 ng/mL) and lower IMA (2128.6±801.8 ng/mL), compared with those in the controls (505.5±231.3 ng/mL and 2466.9±1044.9 ng/mL, respectively); however, the difference was not significant. In the study, we found a weak and negative correlation between adropin and IMA levels in the patients with PE (p=0.020, r=-0.348). Conclusions: In our study among the patients with PE, there was no significant difference between adropin and IMA levels, although serum atropin concentration was high, and IMA concentration was low. So, we consider that both IMA and adropin are the inappropriate markers for the diagnosis of PE.

Keywords

• Adropin
• , ischemia-modified albümin
• oxidative stress
• pulmonary embolism
• receiver operating characteristics

References

1. Root CW, Dudzinski DM, Zakhary B, Friedman OA, Sista AK, et al. Multidisciplinary approach to the management of pulmonary embolism patients: the pulmonary embolism response team (PERT). J Multidiscip Healthc. 2018;5;11:187-95.
2. Morrone D, Morrone V. Acute pulmonary embolism: focus on the clinical picture. Korean Circ J. 2018;48(7):661-3.
3. Kaya Z, Kayrak M, Gul EE, Altunbas G, Toker A, et al. The role of ischemia modified albumin in acute pulmonary embolism. Heart Views. 2014;15(4):106-10.
4. Inal ZO, Erdem SS, Gederet Y, Duran C, Kucukaydın Z, et al. The impact of serum adropin and ischemia modified albümin levels based on BMI in PCOS. Endokrynol Pol. 2018;69(2):135-41.
5. Yamamoto T. Management of patients with high-risk pulmonary embolism: a narrative rewiew. J Intensive Care. 2018 Mar 2;6:16.
6. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur Heart J. 2008;29:2276-315.
7. Meyer G. Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes, Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):406-14.
8. Waleed KB, Guan X, Li X, Yang Y, Wang Z, et al. Atrial fibrilation is related to lower incidence of deep venous thrombosis in patients with pulmonary embolism. J Thorac Dis. 2018;10(3):1476-82.

9. Noschang J, Guimarães MD, Teixeira DFD, Braga JCD, Hochhegger B, et al. Pulmonary thromboembolism: new diagnostic imaging techniques. Radiol Bras. 2018;51(3):178-86.
10. Raji H, JavadMoosavi SA, Dastoorpoor M, Mohamadipour Z, Mousavi Ghanavati SP. Overuse and underuse of pulmonary CT angiography in patients with suspected pulmonary embolism. Med J Islam Repub Iran. 2018:4;32:3.
11. Bozic J, Borovac JA, Galic T, Kurir TT, Supe-Domic D, et al. Adropin and Inflammation Biomarker Levels in Male Patients With Obstructive Sleep Apnea: A Link With Glucose Metabolism and Sleep Parameters, J Clin Sleep Med. 2018;15;14(7):1109-18.
12. Zhao LP, You T, Chan SP, Chen JC, Xu WT. Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Exp Ther Med. 2016;11(3):1065-70.
13. Hu W, Chen L. Association of Serum Adropin Concentrations with Diabetic Nephropathy. Mediators Inflamm. 2016;2016:6038261.
14. Lian W, Gu X, Qin Y, Zheng X. Elevated plasma levels of adropin in heart failure patients. Intern Med. 2011;50(15):1523-7.
15. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-81.
16. Aydin S, Kuloglu T, Aydin S, Kalayci M. Elevated adropin: a candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. Peptides. 2014;58:91-7.
17. Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article. Iran J Public Health. 2016;45(12):1568-76.
18. Zhao LP, You T, Chan SP, Chen JC, Xu WT. Adropin is associated with hyperhomocysteine and coronary atherosclerosis. Exp Ther Med. 2016;11(3):1065-70.
19. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010;14;122(11):185-92.
20. Liu MY, Ballard DW, Huang J, Rauchwerger AS, Reed ME, et al. Acute pulmonary embolism in emergency department patients despite therapeutic anticoagulation. West J Emerg Med. 2018;19(3):510-16.
21. Gök M, Kundi H, Kızıltunç E, Topcuoglu C, Ornek E. The relationship between ischaemia-modified albumin and good coronary collateral circulation. Kardiol Pol. 2018;76(2):370-5.
22. Dogru M, Akoglu H, Kilinckaya MF, Ulfer G. Ischemia-modified albumin levels in children with asthma: a pilot study. Arch Argent Pediatr. 2018;1;116(4).
23. Güldoğan CE, Kılıç MÖ, Balamir İ, Tez M, Turhan T. Correlation between ischemia-modified albumin and Ranson score in acute pancreatitis. Ulus Travma Acil Cerrahi Derg. 2017;23(6):472-76.
24. Özcan O, Erdal H, İlhan G, Demir D. Plasma Ischemia-Modified Albumin Levels and Dynamic Thiol/Disulfide Balance in Sickle Cell Disease: A Case-Control Study. Turk J Haematol. 2018;13;35(4):265-70.
25. Wahab M. Ischemia modified albumin (IMA) in acute coronary syndrome (ACS) and left bundle branch block (LBBB). Does it make the difference?. Egypt Heart J. 2017;69(3):183-90.
26. Batmaz E, Edis EÇ, Eskiocak S, Hatipoğlu ON, Kaya S. The Diagnostic Value of Oxidative Stress Products in Pulmonary Embolism. Tur Toraks Der. 2011;12.3:100-4.
27. Kaya Z, Kayrak M, Gul EE, Altunbas G, Toker A, et al. The role of ischemia modified albumin in acute pulmonary embolism. Heart Views. 2014;15(4):106-10.
28. Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, et al. Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med. 2007;25(7):770-3.
29. Turedi S, Gunduz A, Mentese A, Topbas M, Karahan SC, et al. The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res. 2008;30;9:49.